Company intelligence / Profile preview
British Biotech
Oxford, United Kingdom
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
British Biotech's main development drugs were marimastat (a matrix metalloprotease inhibitor for cancer treatment) and lexipafant (Zacutex, for pancreatitis). Batimastat (BB94) progressed to Phase 3 clinical trials. The company was later found to have misled the public about marimastat's progress, and development of Zacutex was abandoned due to poor clinical trial results.
- Therapeutic areas
- OncologyImmunologyGastroenterologyCardiovascularInfectious Diseases
- Modalities
- Small moleculesMatrix metalloprotease inhibitors
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Schering-Plough Corporation
Beyond the preview
Go deeper on British Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on British Biotech.